Homechevron_rightNewschevron_rightMedia Releasechevron_rightHatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

31 October 2013

Posted in — Media Release

Share

Learn More

Posted in — Media Release

Share

chevron_leftPreviosly

Lice feel the itch over Hatchtech deal

01 November 2013

Nextchevron_right

Tips for women entrepreneurs pitching for investment from a VC

23 October 2013

View All

Subscribe to our Newsletter for the latest updates from 1V.

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

Lice feel the itch over Hatchtech deal

Tips for women entrepreneurs pitching for investment from a VC

You may also like

VC-backed women’s health company Madorra to begin clinical trials in Australia

Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards

OneVentures expands team to internationalise its healthcare portfolio

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.